| Literature DB >> 33478979 |
Jennifer N Rauch1,2, Eric Valois1,2, Diego Acosta-Alvear3,2, Maxwell Z Wilson3,2,4, Sabrina C Solley1, Friederike Braig1, Ryan S Lach1, Morgane Audouard1,2, Jose Carlos Ponce-Rojas1, Michael S Costello1, Naomi J Baxter1, Kenneth S Kosik1,2, Carolina Arias1,2.
Abstract
The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly trained personnel, and large upfront investment. Here, we showcase an orthogonal pipeline we call CREST (Cas13-based, rugged, equitable, scalable testing) that addresses some of these hurdles. Specifically, CREST pairs commonplace and reliable biochemical methods (PCR) with low-cost instrumentation, without sacrificing detection sensitivity. By taking advantage of simple fluorescence visualizers, CREST allows a binary interpretation of results. CREST may provide a point-of-care solution to increase the distribution of COVID-19 surveillance.Entities:
Keywords: COVID-19; CRISPR; Cas13; SARS-CoV-2; point of care; testing
Year: 2021 PMID： 33478979 DOI： 10.1128/JCM.02402-20
Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948